Leerink Partnrs Estimates DexCom's Q2 Earnings (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM - Free Report) - Analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for shares of DexCom in a research note issued on Thursday, May 1st. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of $0.45 for the quarter, down from their previous forecast of $0.51. The consensus estimate for DexCom's current full-year earnings is $2.03 per share. Leerink Partnrs also issued estimates for DexCom's Q3 2025 earnings at $0.63 EPS, Q4 2025 earnings at $0.76 EPS, FY2025 earnings at $2.14 EPS, FY2026 earnings at $2.75 EPS and FY2027 earnings at $3.24 EPS.

Several other research analysts have also issued reports on the company. Robert W. Baird dropped their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and upped their price objective for the company from $85.00 to $115.00 in a research report on Monday, February 3rd. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Canaccord Genuity Group raised their price target on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $98.11.

DexCom Trading Up 1.7 %

Shares of DXCM stock traded up $1.35 during trading hours on Monday, reaching $81.62. 5,200,570 shares of the stock were exchanged, compared to its average volume of 4,284,210. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom has a 12-month low of $57.52 and a 12-month high of $132.26. The firm has a market capitalization of $32.00 billion, a price-to-earnings ratio of 57.07, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The company's 50-day moving average price is $71.27 and its 200-day moving average price is $76.93.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The firm had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the previous year, the firm earned $0.32 earnings per share. The firm's quarterly revenue was up 12.5% compared to the same quarter last year.

Insider Buying and Selling at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of DexCom stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. The trade was a 4.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now directly owns 105,602 shares of the company's stock, valued at $7,432,268.76. The trade was a 10.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock worth $4,734,384 over the last quarter. Insiders own 0.32% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom during the fourth quarter valued at about $25,000. Private Trust Co. NA grew its position in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after purchasing an additional 245 shares during the last quarter. Golden State Wealth Management LLC increased its stake in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares in the last quarter. Optiver Holding B.V. purchased a new position in shares of DexCom in the fourth quarter worth $33,000. Finally, TD Private Client Wealth LLC lifted its stake in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.